Sciclone Pharma Backs Year-end 2014 Outlook - Quick Facts

(RTTNews) - Sciclone Pharmaceuticals Inc (SCLN) updated its year-end 2014 guidance and continues to expect non-GAAP earnings in the range of $0.64 to $0.68 per share and sales revenues of $130 million to $135 million, representing an approximate 30% increase of its core business revenue over 2013.

For 2015, the company currently expects sales revenue of $153 million to $158 million, representing an approximately 17% increase over 2014.

In addition, SciClone has a share repurchase program under which its Board of Directors had authorized $65.5 million, of which approximately $65.2 million had been utilized through December 31, 2014, and about $0.3 million remained available. The Board of Directors may consider authorizing additional funds in this program for 2015.